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Abstract
Background Nondisabling cerebrovascular events repre-
sent the largest group of cerebrovascular disease with a
high risk of recurrent stroke. A recent trial demonstrated
that dual-antiplatelet therapy (clopidogrel and aspirin),
compared with aspirin monotherapy, reduced the risk of
recurrent stroke and was not associated with increased risk
of hemorrhagic events. Apixaban, a new oral anticoagulant,
has been proven to be as safe and effective as traditional
anticoagulants while carrying significantly less risk of
intracranial hemorrhage. Patients with transient ischemic
attack (TIA)/minor stroke might benefit from apixaban
treatment; therefore, an adequately powered randomized
study is needed.
Methods and Results The ADANCE [Apixaban Versus
Dual-antiplatelet Therapy (Clopidogrel and Aspirin) in
Acute Non-disabling Cerebrovascular Events] study is a
randomized, double-blind clinical trial with a target
enrollment of 5,500 patients. A 21-day regimen of apix-
aban or of clopidogrel with aspirin followed by clopidogrel
on days 22 through 90 will be administered to randomized
participants with acute TIA or minor ischemic stroke. The
primary efficacy endpoint is the percentage of patients with
any new stroke (ischemic or hemorrhage), including fatal
stroke, at day 21. Study visits will be performed on the day
of randomization, and at days 7, 22, and 90.
Discussion The novel oral anticoagulant apixaban has
been widely used with fewer adverse effects than tradi-
tional anticoagulants. We designed the ADANCE trial to
observe the effects of apixaban on recurrent stroke after
TIA or minor stroke. The results should better guide the
selection of anticoagulant or dual-antiplatelet therapy for
patients with acute TIA or minor ischemic stroke.
1 Introduction
Stroke, the leading cause of acquired disability, affects
15 million people worldwide every year [1]. Transient
ischemic attack (TIA) and acute minor ischemic stroke,
defined as a National Institutes of Health Stroke Scale
(NIHSS) score B3, represent the largest group of cere-
brovascular disease. About 30–40 % of patients with
ischemic stroke have had a prior TIA or minor stroke [2]. A
previous study suggests that the 90-day risk of a subsequent
stroke is 10.5 % after TIA and that almost half of these
strokes could occur within the first 2 days [3]. After a
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minor stroke, the risk of recurrence is as high as 18.5 % at
day 90 [4].
Aspirin, the gold standard of medical care for anti-
platelet therapy, has been used most extensively for
ischemic cerebrovascular diseases. Compared to intrave-
nous tissue plasminogen activator (t-PA), which has a
narrow therapeutic window (up to 4.5 h after symptom
onset) [5], and traditional anticoagulants with a higher risk
of bleeding events, aspirin has a modest effect on acute
ischemic stroke. Compared to placebo, aspirin adminis-
tration shows a slight increase in the risk of cerebral
hemorrhage. The recently published CHANCE (Clopido-
grel in High-risk Patients With Acute Non-disabling
Cerebrovascular Events) study [6] reported superior results
with dual-antiplatelet therapy (DAPT), i.e., superiority of
clopidogrel–aspirin over aspirin monotherapy. DAPT was
not associated with increased hemorrhage events. The
results shed light on the benefits of exploiting more
effective medical therapy for patients suffering non-dis-
abling cerebrovascular diseases.
Traditional anticoagulants have been used to lower the
risk of early recurrent stroke; however, the benefit is
negated by an increasing rate of bleeding complications [7,
8]. Recently, the novel oral anticoagulants have received
extensive attention because of the following advantages
[9]: (1) they directly target the coagulation cascade with
rapid onset/offset of action; (2) fewer adverse effects
(especially lower rates of major hemorrhage); (3) lower
risk for drug–drug interactions; and (4) a more predictable
response. Apixaban, a direct factor Xa inhibitor, as one of
these novel oral anticoagulants, has been approved for
preventing venous thromboembolism after elective hip or
knee replacement in Europe [10] and for reducing the risk
of stroke and dangerous blood clots (systemic embolism) in
patients with atrial fibrillation (AF) by the US Food and
Drug Administration [11]. The ARISTOTLE (Apixaban for
Reduction in Stroke and Other Thromboembolic Events in
Atrial Fibrillation) trial [12] found that apixaban could
reduce the risks of systemic embolism, bleeding events,
and all-cause mortality, with better tolerability in patients
with AF, compared with warfarin treatment. The AVER-
ROES (Apixaban Versus Acetylsalicylic Acid to Prevent
Stroke in Atrial Fibrillation Patients Who Have Failed or
Are Unsuitable for Vitamin K Antagonist Treatment) trial
[13] confirmed that apixaban was associated with more
effective reduction of stroke and a similar risk of major
bleeding compared with aspirin in patients with AF. Hence,
we speculated that apixaban might show better effect on
patients with TIA or acute ischemic stroke.
To date, the effect of apixaban versus DAPT (clopido-
grel and aspirin) on acute non-disabling cerebrovascular
disease is still unconfirmed. In the ADANCE study, we will
enroll patients with TIA and minor ischemic stroke who are
showing particularly high risk for recurrent ischemia, low
risk for hemorrhage, and relatively stable systematic con-
ditions after cerebrovascular event onset. The study was
designed to estimate whether apixaban administration is
superior to DAPT, in order to decrease recurrent stroke in
Chinese patients after TIA and acute minor stroke.
2 Study Objective
An initial 3 weeks of apixaban versus DAPT therapy
(clopidogrel and aspirin) followed by clopidogrel alone in
high-risk patients with acute non-disabling cerebrovascular
event (ClinicalTrials.gov identifier NCT01924325) is a
randomized, double-blind, multicenter, controlled clinical
trial enrolling 5,500 Chinese patients with acute TIA or
minor stroke. The primary objective of the trial is to
determine whether apixaban is safe and could reduce the
risk of any stroke (both ischemic and hemorrhagic) when
initiated within 24 h of symptom onset in high-risk patients
with TIA or minor ischemic stroke as compared with
DAPT.
3 Study Participants
In total, 5,500 patients will be recruited through 100
emergency departments in general hospitals in China. Two
subtypes of patients will be enrolled: (i) acute non-dis-
abling ischemic stroke; and (ii) acute TIA. Ischemic stroke
is defined as an abrupt onset of a neurologic deficit that is
attributable to acute occlusion of an intracranial vessel. The
standard definition of TIA requires that all neurologic signs
and symptoms resolve within 24 h, regardless of whether
there is imaging evidence of new permanent brain injury;
stroke has occurred if the neurologic signs and symptoms
last for [24 h, with image evidence of a new brain
infarction. Informed consent will be supported by a patient
(or next of kin) information leaflet in Chinese. A consul-
tation meeting will be developed by a study physician to
ensure patients and their families understand the study
procedure and consent to participation in the trial [14].
The study has been approved by the Medical Ethical
Reviewing Committee of the Fourth Military Medical
University Medical Center, Xi’an, China. This clinical trial
will be conducted in accordance with the principles laid
down by the 18th World Medical Assembly (Helsinki,
1964) and all applicable amendments laid down by the
World Medical Assemblies and the International Confer-
ence on Harmonization guidelines for Good Clinical
Practice.
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4 Study Population and Procedures
Table 1 shows the inclusion and exclusion criteria of the
ADANCE trial.
Figure 1 shows the trial procedure. Participants with
suspected TIA or minor stroke will first receive a head
computed tomography (CT) to exclude the intracranial
hemorrhage and optional head magnetic resonance imaging
(MRI) ? diffusion weighted imaging (DWI) to confirm the
area of infarction. A certified, trained, licensed physician
investigator will be required to confirm the diagnosis of
TIA or minor ischemic stroke and to calculate the ABCD2
(age, blood pressure, clinical features, duration of TIA, and
presence of diabetes) score for subjects with TIA or the
NIHSS score for subjects with minor stroke. Once a stan-
dardized, structured interview is performed, the data will
be recorded in the case report form for each patient. All
clinical data, biological samples, and radiological images
will be sent to the central study site where a cerebrovas-
cular neurologist will review the data. Demographic,
medical, social, and behavioral variables will be deter-
mined along with baseline medications. Anthropometry
will be conducted with standardized equipment calibrated
on a daily basis.
Patients meeting these criteria and offering informed
consent will be randomized, and the first dose of study
medication will be given within 24 h of symptom onset.
Patients will be randomized into two groups:
1. Receiving a 75 mg dose of clopidogrel and 75 mg
dose of aspirin from day 1 to day 21, with placebo
apixaban twice daily.
2. Receiving apixaban 5 mg twice daily, with placebo
clopidogrel and placebo aspirin from day 1 to day 21.
A reduced dose of apixaban (2.5 mg twice daily) will be
administered if patients have two or more of the following
three factors: advanced age C80 years, elevated serum
creatinine C1.5 mg/dL, and low body weight B60 kg.
From day 22 to day 90, all patients will receive a 75 mg
dose of clopidogrel long-term antiplatelet therapy. Study
visits will be performed at the day of randomization, and at
days 7, 22, and 90. From randomization to follow-up visits,
the following information will be collected: a neurologic
evaluation [modified Rankin Scale (mRS) and NIHSS]; a
Table 1 Inclusion and exclusion criteria
Inclusion criteria
Adult subjects (male or female C18 years old)
Acute non-disabling ischemic stroke (NIHSS B3 at the time of randomization) that can be treated with study drug within 24 h of symptom
onset. Symptom onset is defined by the ‘last see normal’ principle
TIA (neurologic deficit attributed to focal brain ischemia, with resolution of the deficit within 24 h of symptom onset) that can be treated
with investigational medication within 24 h of symptom onset. Symptom onset is defined by the ‘last see normal’ principle
Informed consent signed
Exclusion criteria
Diagnosis of hemorrhage or other pathology, such as vascular malformation, tumor, abscess, or other major non-ischemic brain disease, on
baseline head CT or MRI scan
mRS score [2 at randomization (pre-morbid historical assessment)
NIHSS C4 at randomization
Clear indication for anticoagulation (atrial fibrillation, mechanical cardiac valves, deep venous thrombosis, pulmonary embolism, or known
hypercoagulable state)
Contraindication to investigational medications
Thrombolysis for ischemic stroke within preceding 7 days
History of intracranial hemorrhage
Current treatment (last dose given within 10 days before randomization) with heparin therapy or oral anticoagulation
Gastrointestinal bleed or major surgery within 3 months
Planned or likely revascularization (any angioplasty or vascular surgery) within the next 3 months
TIA or minor stroke induced by angiography or surgery
Severe non-cardiovascular co-morbidity with life expectancy \3 months
Women of child-bearing age not practicing reliable contraception who do not have a documented negative pregnancy test result
Severe renal failure, defined as GFR B30 mL/min or serum creatinine C4 mg/dL
Severe hepatic insufficiency (Child-Pugh score B to C)
CT computed tomography, GFR glomerular filtration rate, MRI magnetic resonance imaging, mRS modified Rankin Scale, NIHSS National
Institutes of Health Stroke Scale, TIA transient ischemic attack
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physical examination, including measurement of weight (in
kg) and vital signs (supine systolic and diastolic blood
pressure, heart rate); a neurological dysfunctions assess-
ment; concomitant medications; and adverse events. For
ensuring the safety of patients during the study, the trial
should be stopped in the following conditions: (i) the rate
of intracranial hemorrhage exceeds 5 % or the rate of other
hemorrhagic events is more than 10 %; or (ii) the rate of
90-day stroke recurrence (ischemic or hemorrhagic) in the
DAPT group is 20 % less than in the apixaban group.
An individual not associated with the trial will use a
computerized random number generator to randomly
assign subjects to group. Allocation concealment will be
ensured by using an opaque, sealed envelope containing the
group assignment.
5 Study Outcomes
The primary efficacy endpoint is the percentage of patients
with any new stroke (ischemic or hemorrhage), including
fatal stroke, at day 21.
Secondary efficacy endpoints include the following:
1. The percentage of patients at day 90 with new clinical
vascular events [ischemic stroke/hemorrhagic stroke/
TIA/myocardial infarction (MI)/vascular death] as a
cluster and evaluated individually;
2. mRS score changes given as a percentage with a score
of 0–2 versus 3–6 at day 90;
3. Changes in NIHSS scores at day 90; and
4. Efficacy endpoints will also be analyzed stratified by
etiologic subtypes (non-intracranial artery diseases vs.
intracranial artery diseases), time randomization (\12
vs. C12 h), qualifying event (TIA vs. minor stroke),
and age (dichotomized at a 5-year cut-point closest to
median age).
Safety endpoints include the following:
1. Moderate to severe bleeding events at day 90, accord-
ing to the GUSTO (Global Utilization of Streptokinase
and T-Pa For Occluded Coronary Arteries) definition,
including fatal bleeding and symptomatic intracranial
hemorrhage, and incidence of symptomatic and
asymptomatic intracranial hemorrhagic events at day
90;
2. Total mortality (for any reason) at day 90; and
Patients with acute TIA or minor stroke
(Within 24 hours of symptoms onset) 
Selection (inclusion + exclusion criteria 
verified) + informed consent signed
Clopidogrel 75mg qd 
Aspirin 75mg qd 
Placebo apixaban bid 
(from day 1 to day 21)
Apixaban 5mg bid 
Placebo clopidogrel qd 
Placebo Aspirin qd 






Clopidogrel 75mg qd (day 22 to day 90)
Fig. 1 Flowchart outlining the
trial protocol. bid twice daily,
qd once daily, TIA transient
ischemic attack
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3. Adverse events/severe adverse events reported by the
investigators.
6 Randomization, Allocation Concealment,
and Blinding
Subject numbers are to be assigned sequentially as each
patient enters the study. After informed consent is received,
patients fulfilling the inclusion criteria will be randomized
by computer-generated random numbers (Microsoft
Excel 2010, Microsoft Corporation, Redmond, WA,
USA) at the statistics research office of the Fourth Military
Medical University. A clinical research associate will make
opaque blinded envelopes (with consecutive numbers) and
deliver them to each participating center. Random alloca-
tion is to be performed within 24 h after a patient is
enrolled. The block size and treatment-assignment table
would not be available to the researchers until the end of
the trial.
The study medication would be stored under the con-
ditions specified on the label in a locked, safe area of the
pharmacy department to prevent unauthorized access. Both
the study medication and the placebo will be indistin-
guishable; they will be manufactured by the same company
with similar appearances, organoleptic characteristics, and
presentations.
In the event of an emergency, an investigator and a
clinical pharmacist would decide whether it is necessary to
unblind the subject’s treatment assignment with the un-
blinding envelopes provided to the hospital. If unblinding
were necessary, the investigator must record the reason, as
well as the date and time of the event. In each participating
center, an independent researcher would be assigned to
collect the trial paper and electronic records. In the central
trial coordinating office, an independent research assistant
would have access to all unblinded data and maintain
confidentiality of patient records.
7 Statistical Considerations
The primary null hypothesis of this trial is as follows: in
patients with TIA or minor ischemic stroke treated with
clopidogrel and aspirin, there is no difference in 90-day
risk of stroke (ischemic or hemorrhagic) in those treated
with a 21-day regimen of apixaban 5 mg twice daily, if
therapy is initiated within 24 h of symptom onset.
The minimum necessary sample size in the trial is
established by the requirement to detect the smallest
expected clinically meaningful treatment difference com-
paring the treatment with placebo. According to previous
clinical studies [4, 15, 16], the 90-day risk of stroke
recurrence in the placebo (aspirin) group is about 14 %
among high-risk TIA (ABCD2 score C4) or minor stroke
patients treated with aspirin within 24 h of symptom onset.
The CHANCE study [6] further indicated that, as compared
with aspirin monotherapy, clopidogrel and aspirin treat-
ment reduced the risk of recurrent stroke by 32 % and was
not associated with increased hemorrhage events. The
results from our preliminary study were used to calculate
the sample size (unpublished data). The ratios of the 90-
day stroke recurrence in the DAPT group and apixaban
group were 10.47 and 7.96 %, respectively. Therefore, we
presume that the 90-day risk of stroke recurrence is 10.5 %
among high-risk TIA or minor stroke patients with clopi-
dogrel–aspirin therapy within 24 h of symptom onset. A
relative risk reduction of 24 % (relative risk with addition
of apixaban is 0.76) is the smallest difference we will
attempt to detect. The following equation was used for






p  2 sin1 ﬃﬃﬃﬃﬃp2p 2
With a two-sided 5 % significance level (a) and an 80 %
power (1-b), p1 of 0.105, p2 of 0.08, and k0.05, 2 of 9.63,
the minimal sample size per group was estimated to be
2,600 patients. About 5,500 participants in total in the two
groups is the final estimated sample size with 5 %
withdrawals (medication non-adherence). Missing values
will remain missing, and patients will be censored at their
last follow-up assessment (time of clinical event, end of
study, or last visit before loss to follow-up).
All analyses will be intent to treat. In these analyses, we
will compare apixaban versus DAPT treatment. Kaplan-
Meier estimates of the cumulative risk of a stroke (ische-
mic or hemorrhagic) event during a maximum of 90 days’
follow-up, with hazard ratios and 95 % confidence inter-
vals calculated using a Cox proportional-hazards model
and the log-rank test to evaluate the treatment effect will be
reported. The Chi-square test of association will be used to
compare groups at baseline as appropriate. Logistic
regression is to be used to determine the significance of the
results obtained. All statistics would be two-sided with
p \ 0.05 considered significant.
8 Study Organization
The progress of the study would be monitored by the Data
and Safety Monitoring Board (DSMB) to ensure the high
standards of ethics and patient safety. The DSMB would
monitor the trial via scheduled and unscheduled reviews,
supervise stopping rules and unmasking, and maintain the
Apixaban for TIA and Acute Minor Stroke 759
confidentiality of internal discussions and validity of the
reports.
An Executive Committee meeting would be organized
to make major decisions. Quality control inspectors are
responsible for inspecting the quality of research sites and
study data periodically, supervising any quality problem
during the trial, and reporting to the Executive Committee.
The members of the Steering Committee, including two
project directors, will be members of the Executive Com-
mittee and will convene monthly (teleconferences or
physical meetings) to review the status of the trial and
available blinded data; they will take appropriate action
regarding the conduct of the study.
An Adjudication Committee charter including mem-
bership, role, and responsibilities is to be approved before
the start of the trial by the Adjudication Committee and the
Executive Committee. This committee will be composed of
Academic Members, including an independent statistician,
who are not otherwise participating in the trial.
9 Discussion
Acute non-disabling cerebrovascular events are common
and often portend a disabling stroke. Recently, a few
effective therapies have been established according to
clinical trials. Aspirin is the mainstay antiplatelet therapy
that has been used in patients with an acute cerebrovas-
cular events [17] for a long time. Clopidogrel, a platelet
adenosine diphosphate receptor antagonist, has been
shown to be as effective for secondary stroke prevention
as aspirin, with a similar rate of ischemic stroke, MI, or
vascular death [18]. Clopidogrel could not produce max-
imal inhibition of platelet aggregation in a conventional
dose (75 mg/day) for 5 days [19]. This delay presents a
problem for an early treatment effect in the management
of patients with acute ischemic stroke. Recently, DAPT
indicated a reduced risk of recurrent stroke and an
acceptable risk of hemorrhage events for high-risk patients
with non-disabling cerebrovascular events [6]. Therefore,
we can’t deny the possibility that there may have been
some other medical regimen that could improve outcomes
in those patients.
Patients administered with traditional anticoagulants
immediately after acute ischemic stroke onset have been
reported to have a lower risk of recurrent stroke and an
increased rate of bleeding complications, as compared with
untreated patients or patients who received an antiplatelet
agent [20, 21]. However, in recent times, novel oral anti-
coagulants, including direct factor Xa inhibitors and direct
thrombin inhibitors, have shown advantage in reducing the
risk of stroke in patients with AF [11, 22] and preventing or
treating venous thromboembolism [10] with fewer
hemorrhagic adverse effects and a preferable response
compared with traditional anticoagulants [9]. Recently,
apixaban (a direct factor Xa inhibitor) has received broad
attention for its reliable anticoagulant effect and lower rates
of major hemorrhage [23]. Compared with warfarin,
apixaban shows better tolerability and a lower rate of
systemic embolism, bleeding events, and all-cause mor-
tality [12]. Compared with aspirin, apixaban has been
found to have a similar risk of major bleeding and reduced
risk of stroke onset in patients with AF [13]. However, the
effects of apixaban on the early recurrent stroke risk after
TIA and acute minor stroke are still uncertain. The
ADANCE trial is a randomized, double-blind, multicenter
controlled clinical trial in China. We will assess the effect
of a 3-month regimen of apixaban treatment for the first
21 days followed by clopidogrel monotherapy versus a
3-month regimen of DAPT for the first 21 days followed
by clopidogrel alone, on reducing the 3-month risk of any
stroke when initiated within 24 h of symptom onset in
high-risk patients with TIA or minor stroke.
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